Hematopoiesis News 7.33 August 23, 2016 | |
| |
TOP STORYCRISPR Gene Editing Reveals New Therapeutic Approach for Blood Disorders An international team of scientists have found a way to use CRISPR gene editing to help fix sickle cell disease and beta-thalassemia in blood cells isolated from patients. The study provides proof-of-principle for a new approach to treat common blood disorders by genome editing. [Press release from St. Jude Children’s Research Hospital discussing online prepublication in Nature Medicine] Press Release | Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)The authors investigated whether the developmental attenuation of B-1a cell output is a consequence of a shift in stem cell state during ontogeny. Using cellular barcoding for in vivo single-cell fate analyses, they found that fetal liver definitive hematopoietic stem cells gave rise to both B-1a and B-2 cells. [Immunity] Abstract | Graphical Abstract | Press Release Peripheral Blood CD34+ Cells Efficiently Engraft Human Cytokine Knock-In Mice Researchers generated so-called MSTRG and MISTRG hu-manized mice on a Rag2-/-Il2rg-/- background carrying a transgene for human SIRPα and human homologues of the cytokines macrophage-colony stimulating factor, thrombopoietin, with or without interleukin-3 and granulocyte-macrophage colony stimulating factor under murine promotors. [Blood] Abstract Investigators cloned and functionally characterized a murine bone marrow mesenchymal stromal/stem cells (MSC) sub-population that was uniformly Nestin+ Lepr+ Sca-1+ CD146+ and could be stably propagated with high CFU-F re-cloning efficiency. [Stem Cells] Abstract Scientists demonstrated the discrimination of specific autocrine and paracrine signals from soluble factors as stimulating and inhibitory effectors in hematopoietic stem and progenitor cell culture. [Sci Rep] Full Article Antineoplastic Effects and Mechanisms of Micheliolide in Acute Myelogenous Leukemia Stem Cells Micheliolide (MCL) is a natural guaianolide sesquiterpene lactone which was discovered in Michelia compressa and Michelia champaca plants, and has been shown to exert selective cytotoxic effects on CD34+CD38– leukemic stem cells. Investigators demonstrated that DMAMCL significantly prolongs the lifespan of a mouse model of human acute myelogenous leukemia. [Oncotarget] Full Article Impact of Oxygen Levels on Human Hematopoietic Stem and Progenitor Cell Expansion Scientists demonstrated that the pO2 experienced by cells in static culture can change dramatically during the course of culture as cell numbers increase, and as the oxygen utilisation by cells exceeds the diffusion of oxygen through the media. [Stem Cells Dev] Abstract CLINICAL RESEARCHResearchers studied 8907 patients with newly diagnosed acute myeloid leukemia and examined outcomes in patients with refractory disease defined using differing criteria which have previously been proposed. [Haematologica] Abstract | Full Article Investigators hypothesized that blocking CXCR4/SDF-1 interaction after hematopoietic stem cell (HSC) transplantation promotes hematopoiesis by inducing HSC proliferation. [J Hematol Oncol] Full Article | |
| |
REVIEWSHematopoietic (Stem) Cell Development: How Divergent Are the Roads Taken? The authors discuss the current knowledge on the step-wise embryonic establishment of the adult hematopoietic system, examine the roles of pivotal intrinsic regulators in this process, and raise questions concerning the temporal onset of hematopoietic stem cells fate determination. [FEBS Lett] Abstract The Embryonic Origins and Genetic Programming of Emerging Hematopoietic Stem Cells The authors review the current knowledge of the origins, lineage relationships, genetic programming, and differentiation of the definitive hemangioblast that leads to the generation of hematopoietic stem cells. [FEBS Lett] Abstract Visit our reviews page to see a complete list of reviews in the hematopoiesis research field. | |
| |
INDUSTRY NEWSGenmab A/S announced that its licensing partner, Janssen Biotech, Inc. has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA) for the use of daratumumab in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who received at least one prior therapy. [Genmab A/S] Press Release MolMed S.p.A. announced that the European Commission has granted a Conditional Marketing Authorisation for Zalmoxis, the first immunogene therapy, as patient-specific adjunctive treatment in haplo-identical haematopoietic stem-cell transplantation for adult patients with high-risk haematological malignancies. [MolMed S.p.A.] Press Release | |
| |
POLICY NEWSPutin Appoints Church Historian as Science Minister Russian President Vladimir Putin has appointed a church historian as the country’s new science and education minister. The president announced that Olga Vasilyeva would succeed the current science minister, Dmitry Livanov, who will become presidential envoy on trade and economic relations with Ukraine, according to the Russian news agency Interfax. [Nature News] Editorial Obama’s Science Legacy: Betting Big on Biomedical Science Ambitious bids to map the brain and cure cancer have not boosted overall research funding. [Nature News] Editorial US Personalized-Medicine Industry Takes Hit From Supreme Court Rejections for US patents related to personalized medicine have spiked after recent Supreme Court decisions tightened the rules for such claims, an analysis of more than 39,000 patent applications reveals. [Nature News] Editorial Chemistry Group Throws out Election Results after Fears of Vote Rigging Members of the Society of Biological Inorganic Chemistry are reacting with puzzlement and shock after learning that the results of a recent online leadership election have been thrown out because of voting irregularities—raising concerns over possible manipulation. [ScienceInsider] Editorial Updated: Companies Settle Gene Technology Patent Fight that Was Shrouded in Mystery Illumina Inc. and Oxford Nanopore Technologies have reached a settlement in this legal battle, according to a U.S. International Trade Commission document released last week. Oxford has agreed not to import or sell any product containing a pore with an amino acid sequence at least 68% similar to Mycobacterium smegmatis porin — the protein at the heart of Illumina’s infringement claim — and to destroy any inventory of such products. [ScienceInsider] Editorial Obama’s Science Legacy: Uneven Progress on Scientific Integrity Many researchers who watched Barack Obama’s inauguration in 2009 were thrilled by his pledge to “restore science to its rightful place”. But scientists and legal scholars say that, in many ways, Obama has failed to live up to that lofty promise. [Nature News] Editorial
| |
EVENTSNEW 21st Annual Congress of Asia Pacific Blood and Marrow Transplantation Group 2016 (APBMT 2016) NEW 3rd Congress on Controversies in Thrombosis and Hemostasis (CiTH) NEW 7th International Conference on Stem Cells and Cancer (ICSCC-2016): Proliferation, Differentiation and Apoptosis Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Position – Gene Regulation in Hematopoietic Differentiation (Charles University) NEW Research Technologist (Pennsylvania State University) Technical Sales Representative (STEMCELL Technologies Inc.) Postdoctoral Stipend – Development of Immune System (Lund University) Postdoctoral Research Scientist (National Taiwan University) Postdoctoral Position – Tumor Immunology (Roswell Park Cancer Institute) Postdoctoral Fellow – Hematopoietic Stem Cells (University of Pennsylvania) Assistant Member Faculty – Platinum/Immunotherapy (Fred Hutchinson Cancer Research Center) Cytogenetics Laboratory Supervisor (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Hematopoiesis News Volume 7.33 | Aug 23 2016